Earnings intelligence

Earnings Signals

15s fallback

A clear read on the latest earnings surprise, its evidence, and what could invalidate the call.

BIIB

BIOGEN INC.

FY2026 · Q3 · reaction revision

Updated
Bullish signal

Long bias

EPS beat estimates by 32.3%; Revenue beat estimates by 6.3%; guidance raised; fresh reaction +0.5%.

Evidence coverage

100%

Completeness,
not win probability

Release
mixed
Guidance
raised
Market reaction
+0.49%

EPS

2.62

Consensus 1.98 USD/share

REVENUE

2,800

Consensus 2,634.809 USDm

Recent signals

Today’s reports

Why the model sees it this way

  • EPS: 2.62 reported vs 1.98 consensus · above consensus.
  • REVENUE: 2,800 reported vs 2,634.809 consensus · above consensus.
  • Guidance was raised.
  • The measured market reaction was +0.49%.

Risks & open questions

  • Still missing: standardized eps surprise.
  • Still missing: reaction spread bps.

Signal track record

Research

Current verdict

Profitability is not established

No current-model directional call has resolved yet. PREVICT cannot honestly claim this signal is profitable or unprofitable.

Resolved calls

0 / 200

minimum evidence gate

Evidence history2 revisions

Revision history

  1. Revision 1 · fast release · positive ·
  2. Revision 2 · reaction revision · positive ·